S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains

GeoVax Labs Stock Price, News & Analysis (NASDAQ:GOVX)

$0.43
0.00 (0.00%)
(As of 11/30/2023 ET)
Compare
Today's Range
$0.41
$0.44
50-Day Range
$0.43
$0.59
52-Week Range
$0.41
$1.39
Volume
187,936 shs
Average Volume
722,290 shs
Market Capitalization
$11.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

GeoVax Labs MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,300.2% Upside
$6.00 Price Target
Short Interest
Healthy
2.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of GeoVax Labs in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$5,020 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.73) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

272nd out of 949 stocks

Pharmaceutical Preparations Industry

107th out of 433 stocks


GOVX stock logo

About GeoVax Labs Stock (NASDAQ:GOVX)

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

GOVX Stock Price History

GOVX Stock News Headlines

GeoVax to Participate in Upcoming December Investor Events
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Geovax Labs Earnings Preview
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
GeoVax Labs Secures License Agreement With ProBioGen
GeoVax Labs (GOVX) Gets a Buy from Noble Financial
GeoVax Announces Issuance of Ebola Vaccine Patent
See More Headlines
Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOVX
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,300.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,020,000.00
Pretax Margin
-2,375,800.00%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.34 per share

Miscellaneous

Free Float
25,627,000
Market Cap
$11.44 million
Optionable
Not Optionable
Beta
2.93
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. David Alan Dodd (Age 73)
    Chairman, President & CEO
    Comp: $469.01k
  • Mr. Mark W. Reynolds CPA (Age 61)
    CFO & Corporate Secretary
    Comp: $348.2k
  • Dr. Mark J. Newman Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $364.17k
  • Dr. Harriet Latham Robinson Ph.D. (Age 85)
    Founder & Member of Scientific Advisory Board
  • Dr. Kelly T. McKee Jr. (Age 73)
    M.D., M.P.H., Chief Medical Officer
  • Jeffrey Welch
    Head of Process Development & Manufacturing Operations
  • Dr. John W. Sharkey Ph.D. (Age 67)
    Vice President of Business Development














GOVX Stock Analysis - Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOVX shares.
View GOVX analyst ratings
or view top-rated stocks.

What is GeoVax Labs' stock price target for 2024?

2 brokers have issued 1 year target prices for GeoVax Labs' shares. Their GOVX share price targets range from $4.00 to $8.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,300.2% from the stock's current price.
View analysts price targets for GOVX
or view top-rated stocks among Wall Street analysts.

How have GOVX shares performed in 2023?

GeoVax Labs' stock was trading at $0.6302 at the beginning of 2023. Since then, GOVX shares have decreased by 32.0% and is now trading at $0.4285.
View the best growth stocks for 2023 here
.

Are investors shorting GeoVax Labs?

GeoVax Labs saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 634,200 shares, a decrease of 24.2% from the October 31st total of 836,900 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is currently 3.0 days.
View GeoVax Labs' Short Interest
.

When is GeoVax Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our GOVX earnings forecast
.

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) posted its earnings results on Wednesday, November, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.15.

How do I buy shares of GeoVax Labs?

Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GOVX) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -